Live Analyst Rating Changes 24956 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eugene Mannheimer
FREE

Eugene Mannheimer

Freedom Capital Markets
Wall Street Analyst
★★★☆☆
#2009
on 13Foresight · ranked by our own returns
42%
Success Rate
+26.9%
Average Return
5 of 12 calls profitable · +17.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 42% of Eugene Mannheimer's ratings turned a profit when each position was held for 1 year — averaging +26.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

3 Buy 2 Hold 0 Sell
Eugene's Stock Coverage 15 ratings · 2026-08-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
TEM
Tempus AI, Inc. Class A
 Jun 30, 2026 HOLD Buy
+24.1% avg upside
21 analysts
$59.00
13.19% Upside
 -10.1% ·
DOCS
Doximity
 Mar 17, 2026 BUY Buy
+35.6% avg upside
28 analysts
$31.00
24.99% Upside
 -0.4% ·
HNGE
Hinge Health, Inc. Class A
 Jan 22, 2026 BUY Strong Buy
+7.8% avg upside
17 analysts
$59.00
33.28% Downside
 +111.9% ·
WAY
Waystar Holding Corp.
 Nov 20, 2025 HOLD Strong Buy
+49.0% avg upside
30 analysts
$40.00
61.52% Upside
 -28.8% ·
IRTC
Irhythm Technologies
 Oct 13, 2025 BUY Strong Buy
+32.4% avg upside
20 analysts
$205.00
62.10% Upside
 -28.7% ·
CCSI
Consensus Cloud Solutions
 Feb 24, 2025 BUY Hold
-17.3% avg upside
6 analysts
$38.00
2.71% Downside
 +16.4% ·
OMCL
Omnicell
 Nov 21, 2024 BUY Strong Buy
+31.4% avg upside
12 analysts
$52.00
39.51% Upside
 -18.4% ·
NUTX
Clinigence Holdings
 Nov 21, 2024 BUY Strong Buy
+23.5% avg upside
5 analysts
$56.00
70.03% Downside
 +329.3% ·
SCNX
Scienture Holdings
 Jul 27, 2021 BUY Strong Buy
+2274.6% avg upside
4 analysts
$8.00
1642.92% Upside
 · ·
UPHL
UpHealth
 Jul 13, 2021 BUY Strong Buy
+2683233.3% avg upside
6 analysts
$13.00
4333233.33% Upside
 · ·
ASTH
Astrana Health
 Jun 24, 2021 BUY Strong Buy
+46.6% avg upside
16 analysts
$75.00
83.85% Upside
 -33.3% ·
CCLD
CareCloud
 Jun 22, 2021 BUY Strong Buy
+233.0% avg upside
9 analysts
$12.00
363.29% Upside
 -59.6% ·
OTRKQ
Ontrak
 May 07, 2021 BUY Hold
+21716566.7% avg upside
7 analysts
$42.00
41999899.95% Upside
 · ·
MDRX
Veradigm
 May 03, 2021 BUY Buy
+199.9% avg upside
22 analysts
$18.00
267.32% Upside
 +26.5% ·
MCK
McKesson
 May 01, 2012 HOLD Strong Buy
-12.2% avg upside
28 analysts
$98.00
88.70% Downside
 +17.9% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Eugene Mannheimer — Frequently Asked Questions
How accurate are Eugene Mannheimer's stock ratings?
Based on the calls 13Foresight could measure, about 42% of Eugene's ratings were profitable over a one-year hold, with an average return of +26.9% per rating, or +17.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Eugene ranked on 13Foresight?
Eugene Mannheimer is currently ranked #2009 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eugene cover?
Eugene most recently has ratings on TEM, DOCS, HNGE, WAY, IRTC, CCSI, OMCL, NUTX, SCNX, UPHL, ASTH, CCLD and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.